Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
27) Astellas Pharma 2022 Revenue: Astellas Pharmas annual revenue for the year ended March 31, 2023, was $1.52 trillion JPY ($11.55 billion USD), a 17.16 percent increase from $1.30 trillion JPY ($11.80 billion USD) for the year ended March 31, 2022
Karacabeyli D, Lacaille D
You may not place drug or supplement advertising adjacent to our story
Company-reported Phase 3 topline results have circulated in 20252026, and a regulatory filing has been anticipated, but retatrutide is not FDA- or EMA-approved and is not available as a prescription product
The most commonly reported GI AEs include nausea, diarrhoea, vomiting, and constipation, which are typically mild to moderate in intensity and transient in duration [13, 38, 40,41,42,43,44,45,46, 52]
Safety Profile in Research: GHK-Cus natural occurrence in the human body and its well-characterised copper-binding chemistry have contributed to a favourable pre-clinical safety profile in research models, supporting its continued use as a broadly applicable research tool across multiple biological systems
US$ 25.74
US$ 24.99
US$ 24.55
US$ 25.43
US$ 20.22
US$ 25.89
US$ 25.23
US$ 23.56
US$ 22.12
US$ 27.86
